.Pharmacolibrary.Drugs.ATC.V.V03AX03 .Pharmacolibrary.Drugs.ATC.V.V03AX03| name: | Cobicistat |
| ATC code: | V03AX03 | route: | oral |
| n-compartments | 1 |
Cobicistat is a potent, selective inhibitor of cytochrome P450 3A (CYP3A) enzymes used as a pharmacokinetic enhancer (booster) for certain antiretroviral drugs, particularly HIV-1 protease inhibitors (such as atazanavir, darunavir) and the integrase inhibitor elvitegravir. Cobicistat has no activity against HIV-1 itself and is not used as monotherapy. It is currently approved and used in combination with other antiretrovirals.
Pharmacokinetic parameters in healthy adult volunteers, mixed sex, single dose under fasting and fed (high fat meal) conditions.
Eisenmann, ED, et al., & Baker, SD (2021). Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. Cancer research communications 1(2) 79–89. DOI:10.1158/2767-9764.crc-21-0076 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34950932
Yamada, H, et al., & Irie, S (2018). Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects. Clinical pharmacology in drug development 7(2) 132–142. DOI:10.1002/cpdd.365 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28581645
Ogbuagu, O (2016). Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert review of anti-infective therapy 14(12) 1113–1126. DOI:10.1080/14787210.2016.1255551 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27797606